Open access
Open access
Powered by Google Translator Translator

Heart Failure/Transplantation

Clinical risk score to predict pathogenic genotypes in patients with dilated cardiomyopathy.

26 Sep, 2022 | 11:57h | UTC

Clinical Risk Score to Predict Pathogenic Genotypes in Patients With Dilated Cardiomyopathy – Journal of the American College of Cardiology

Editorial: Genetic Testing for Dilated Cardiomyopathy: Old School Is New School – Journal of the American College of Cardiology

News Release: Scientists develop a tool to determine if dilated cardiomyopathy has a genetic origin  – Centro Nacional de Investigaciones Cardiovasculares Carlos III

 

Commentary on Twitter

 


M-A | Optimal pharmacologic treatment of heart failure with preserved and mildly reduced ejection fraction.

22 Sep, 2022 | 13:05h | UTC

Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis – JAMA Network Open

Related M-A: SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials – The Lancet (link to abstract – $ for full-text)

 


A simple score to identify increased risk of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction.

20 Sep, 2022 | 13:16h | UTC

A Simple Score to Identify Increased Risk of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction – JAMA Cardiology (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Guideline Synopsis | AHA/ACC Guideline for the management of heart failure.

16 Sep, 2022 | 13:01h | UTC

Management of Heart Failure – JAMA (free for a limited period)

Original Article: #ACC22 – 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.

 


Retrospective Cohort Study | Natural history of MYH7-related dilated cardiomyopathy.

14 Sep, 2022 | 13:06h | UTC

Natural History of MYH7-related Dilated Cardiomyopathy – Journal of the American College of Cardiology

 


Five-year outcomes in patients with fully magnetically levitated vs. axial-flow left ventricular assist devices in the MOMENTUM 3 randomized trial.

11 Sep, 2022 | 22:43h | UTC

Five-Year Outcomes in Patients With Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized Trial – JAMA (free for a limited period)

 

Commentary on Twitter

 


Large study unravels the risk factors for heart failure among childhood cancer survivors.

11 Sep, 2022 | 22:22h | UTC

Risk Factors for Heart Failure Among Pan-European Childhood Cancer Survivors – Journal of Clinical Oncology

 


#ESCCongress – M-A | Patients with heart failure benefit from dapagliflozin regardless of ejection fraction.

30 Aug, 2022 | 12:14h | UTC

News Release: Patients with heart failure benefit from dapagliflozin regardless of ejection fraction – European Society of Cardiology

Original Study: Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER – Nature Medicine

Related:

#ESCCongress – RCT | Dapagliflozin reduced the risk of worsening heart failure or cardiovascular death in patients with heart failure with mildly reduced or preserved ejection fraction.

Randomized Trial: SGLT2 Inhibitor Improves Outcomes in Patients with Heart Failure Even in the Absence of Diabetes

 


#ESCCongress – RCT | In patients with severe ischemic left ventricular systolic dysfunction under optimal medical therapy, revascularization by PCI did not improve outcomes.

29 Aug, 2022 | 12:38h | UTC

Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Coronary stenting does not benefit patients with severe left ventricular dysfunction – European Society of Cardiology

Commentary: DANCAVAS: CV Screening Did Not Significantly Reduce Incidence of Death in Older Males – American College of Cardiology

 

Commentary on Twitter

 


#ESCCongress – RCT | Dapagliflozin reduced the risk of worsening heart failure or cardiovascular death in patients with heart failure with mildly reduced or preserved ejection fraction.

29 Aug, 2022 | 12:36h | UTC

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Dapagliflozin benefits patients with mildly reduced and preserved ejection fraction – European Society of Cardiology

Related (#ESCCongress 2021): RCT: SGLT2 inhibition reduced the combined risk of cardiovascular death or hospitalization in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.

 

Commentary on Twitter

 


#ESCCongress – Meta-analysis of randomized trials | SGLT-2 inhibitors in patients with heart failure.

29 Aug, 2022 | 12:35h | UTC

SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials – The Lancet (free registration required)

 

Commentary on Twitter

 


RCT | Acetazolamide resulted in faster decongestion in patients with acute decompensated heart failure with volume overload.

29 Aug, 2022 | 12:25h | UTC

Acetazolamide in Acute Decompensated Heart Failure with Volume Overload – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Acetazolamide improves decongestion in patients with acute decompensated heart failure – European Society of Cardiology

Commentary: Acetazolamide in Decompensated Heart Failure With Volume Overload – ADVOR – American College of Cardiology

 

Commentary on Twitter

 


Secondary analysis of a RCT | Effects of Empagliflozin on symptoms, physical limitations, and quality of life in patients hospitalized for acute heart failure.

26 Aug, 2022 | 13:24h | UTC

Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial – Circulation

Commentary: Empagliflozin Offers Clinical Benefit in Heart Failure – HealthDay

Original Study: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial – Nature Medicine

 


Observational study suggests Hydroxychloroquine is associated with increased risk of cardiovascular events compared to Methotrexate in patients with heart failure.

25 Aug, 2022 | 11:56h | UTC

Cardiovascular Risks of Hydroxychloroquine vs Methotrexate in Patients With Rheumatoid Arthritis – Journal of the American College of Cardiology (link to abstract – $ for full-text)

Editorial: Hydroxychloroquine: Heart-Throb No More? – Journal of the American College of Cardiology

Commentary: Caution needed with hydroxychloroquine use in older RA patients with heart failure – medwire News

 


Left ventricular assist devices: a primer for the non-mechanical circulatory support provider.

17 Aug, 2022 | 13:51h | UTC

Left Ventricular Assist Devices: A Primer for the Non-Mechanical Circulatory Support Provider – Journal of Clinical Medicine

 


RCT | Sustained-release ivabradine hemisulfate in patients with systolic heart failure.

16 Aug, 2022 | 13:01h | UTC

Sustained-Release Ivabradine Hemisulfate in Patients With Systolic Heart Failure – Journal of the American College of Cardiology

 


RCT | Omecamtiv Mecarbil does not improve exercise capacity in chronic heart failure with reduced ejection fraction.

15 Aug, 2022 | 12:07h | UTC

Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)

Author Interview: Can Omecamtiv Mecarbil Improve Peak Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF)? – JAMA

Commentaries:

Omecamtiv Mecarbil Fails to Improve Exercise Capacity in HFrEF – Medscape (free registration required)

Omecamtiv mecarbil not associated with improved exercise capacity compared with placebo in patients with chronic heart failure with reduced ejection fraction – Physician’s Weekly

Related: #AHA20 – Randomized trial: In patients with systolic heart failure, Cardiac Myosin activation with Omecamtiv Mecarbil led to modest reduction in heart failure events

 

Commentary on Twitter

 


Cohort Study | Age at menopause and risk of heart failure and atrial fibrillation.

5 Aug, 2022 | 14:38h | UTC

Age at menopause and risk of heart failure and atrial fibrillation: a nationwide cohort study – European Heart Journal (link to abstract – $ for full-text)

Editorial: Premature menopause and cardiovascular disease: can we blame estrogen? – European Heart Journal

News Release: Premature menopause is associated with increased risk of heart problems – European Society of Cardiology

 


RCT | Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction.

3 Aug, 2022 | 14:06h | UTC

Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial – European Society of Cardiology

 

Commentary on Twitter

 


Review | Management of heart failure in patients with chronic kidney disease.

1 Aug, 2022 | 11:59h | UTC

Management of Heart Failure in Patients with Chronic Kidney Disease – European Cardiology Review

 


M-A | Mortality and clinical predictors after percutaneous mitral valve repair for secondary mitral regurgitation.

26 Jul, 2022 | 11:49h | UTC

Mortality and Clinical Predictors After Percutaneous Mitral Valve Repair for Secondary Mitral Regurgitation: A Systematic Review and Meta-Regression Analysis – Frontiers in Cardiovascular Medicine

 


Development and validation of a decision support tool for the diagnosis of acute heart failure: systematic review, meta-analysis, and modelling study.

22 Jul, 2022 | 11:18h | UTC

Development and validation of a decision support tool for the diagnosis of acute heart failure: systematic review, meta-analysis, and modelling study – The BMJ

 

Commentary from the author on Twitter

Under a http://creativecommons.org/licenses/by/4.0/ license

 


Review | Temporary mechanical circulatory support: devices, outcomes, and future directions.

14 Jul, 2022 | 12:23h | UTC

Temporary mechanical circulatory support: Devices, outcomes, and future directions – The Journal of Heart and Lung Transplantation

 


RCT | Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy.

13 Jul, 2022 | 11:52h | UTC

Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy – Journal of the American College of Cardiology

Related: #ACC22 [Not published yet] – RCT: Mavacamten reduces the need for surgical intervention in patients with obstructive hypertrophic cardiomyopathy.

 


AHA Science Advisory | Elucidating the clinical implications and pathophysiology of pulmonary hypertension in heart failure with preserved ejection fraction: a call to action.

13 Jul, 2022 | 11:40h | UTC

Elucidating the Clinical Implications and Pathophysiology of Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Call to Action: A Science Advisory From the American Heart Association – Circulation

 


Stay Updated in Your Specialty

No spam, just news.